AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Learn more →

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients

Phase 3

Completed

Conditions: Diabetic Macular Edema
Visual Impairment

Interventions: Drug: Ranibizumab (RFB002)
Procedure: Laser
Procedure: Sham laser
Drug: Sham injection

First Posted Date: 2014-10-08

Last Posted Date: 2019-02-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 384

Registration Number: NCT02259088

Locations: 🇨🇳
Novartis Investigative Site, Shanghai, China

Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

Phase 4

Withdrawn

Conditions: Visual Impairment Due to Diabetic Macular Edema

Interventions: Drug: Ranibizumab
Drug: Aflibercept

First Posted Date: 2014-10-07

Last Posted Date: 2016-10-27

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT02258009

Locations: 🇩🇪
Novartis Investigative Site, Chemnitz, Germany

Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration

Phase 4

Completed

Conditions: Wet Age-Related Macular Degeneration

Interventions: Drug: Ranibizumab 0.5 mg
Drug: Aflibercept 2 mg

First Posted Date: 2014-10-06

Last Posted Date: 2019-05-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 41

Registration Number: NCT02257632

Locations: 🇩🇪
Novartis Investigative Site, Regensburg, Germany

Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients

Phase 1

Completed

Conditions: Chronic Myeloid Leukemia

Interventions: Drug: Nilotinib
Drug: Ruxolitinib

First Posted Date: 2014-10-01

Last Posted Date: 2019-05-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 5

Registration Number: NCT02253277

Locations: 🇩🇪
Novartis Investigative Site, Leipzig, Germany

Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

Phase 2

Completed

Conditions: Sporadic Inclusion Body Myositis (sIBM)

Interventions: Drug: BYM338 (Bimagrumab)

First Posted Date: 2014-09-26

Last Posted Date: 2020-12-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 10

Registration Number: NCT02250443

Locations: 🇺🇸
Novartis Investigative Site, Boston, Massachusetts, United States

Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.Aeruginosa

Phase 4

Terminated

Conditions: Chronic Lung Infection With Pseudomonas Aeruginosa in Cystic Fibrosis

Interventions: Drug: TIS or TIP

First Posted Date: 2014-09-25

Last Posted Date: 2018-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 17

Registration Number: NCT02248922

Locations: 🇩🇪
Novartis Investigative Site, Jena, Germany

A First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of QCC374

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: QCC374
Drug: Placebo

First Posted Date: 2014-09-22

Last Posted Date: 2016-03-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 66

Registration Number: NCT02245828

Locations: 🇬🇧
Novartis Investigative Site, Mid Glamorgan, Wales, United Kingdom

Study of Afuresertib Combined With Paclitaxel in Gastric Cancer

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: Afuresertib
Drug: Paclitaxel

First Posted Date: 2014-09-15

Last Posted Date: 2017-04-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 29

Registration Number: NCT02240212

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)

Phase 4

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: QVA149
Drug: QVA149 Placebo

First Posted Date: 2014-09-08

Last Posted Date: 2018-08-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 38

Registration Number: NCT02233543

Locations: 🇸🇪
Novartis Investigative Site, Uppsala, Sweden

Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks

Phase 4

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Fingolimod

First Posted Date: 2014-09-04

Last Posted Date: 2021-02-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 6

Registration Number: NCT02232061

Locations: 🇮🇹
Novartis Investigative Site, Napoli, Italy

Home Terms & Conditions Privacy Policy